Skip to content
  • About us
  • For advertising
  • For authors
  • Publishing ethics
  • Contacts
  • GDPR
  • български
Shopping Cart 0
Facebook
GPNews
  • Home
  • IssuesExpand
    • 2025
    • 2024
    • 2023
    • 2022
  • Article summariesExpand
    • AG and Neonatology
    • Allergology
    • Dental Health
    • Cardiology
    • Dermatology and Cosmetics
    • Endocrinology
    • From the Practice
    • Gastroenterology
    • History Teaches
    • In the World of Viruses
    • Nature Teaches
    • Neurology and Psychiatry
    • Nutrition, Dietetics, Metabolism
    • Oncology
    • Ophtalmology
    • Others
    • Otorhinolaryngology and Pulmonary Diseases
    • Pediatrics
    • Rheumatology and Diseases of the Joints
    • Test on a Clinical Case
    • Urology and Nephrology
  • Subscription
Shopping Cart 0
Facebook

  • български

GPNews
Home / Others / New directions in the pharmacotherapy of obesity through the second generation of anti-obesity drugs

New directions in the pharmacotherapy of obesity through the second generation of anti-obesity drugs

отGP News публикувано на 30.11.202212.01.2023 Others
фармакотерапията на затлъстяването

Issue 11/2022

T. Khandzhieva-Durlenska
Department of Pharmacology and Toxicology, Faculty of Medicine, Medical University – Sofia

Obesity is a chronic relapsing disease. The main goal in the obesity treatment is not the quantity of weight loss as an endpoint itself, but rather the prevention and treatment of complications to ameliorate health and decrease morbidity and mortality. This perspective is consistent with the ne obesity guidelines and the new diagnostic term adiposity-based chronic disease (ABCD). Many complications require 10-20% weight loss to achieve therapeutic goals. In Jube 2021, semaglutide 2.4 mg/ week was approved for chronic weight management. Phase 3 clinical trials demonstrate that this medication produced >10% placebo-subtracted weight loss, more than half of patients lost ≥15%, and over one third lost ≥20 % of baseline weight. These data double effectiveness over existing obesity medications, provides sufficient weight loss to ameliorate a broad range of complications, and qualifies as the first member of a second-generation class of obesity medications. The second-generation anti-obesity drugs fully enable to treat-to-target approach for management of ABCD. Moreover, the second-generation anti-obesity drug permits active management of body weight as a biomarker to targets associated with effective treatment and prevention of specific complications. ABCD can be now treated similar to other chronic diseases such as diabetes mellitus type 2, arterial hypertension, and atherosclerosis which are treated to specific biomarker targets (e.g. HbA1c, blood pressure, and LDL-cholesterol) to prevent the respective complications of these diseases.

Address for correspondence:
Assoc. prof. Teodora Handjieva-Darlenska
Department of pharmacology and toxicology,
Medical faculty, Medical university, Sofia
2, Zdrave, Str.
1433, Sofia
e-mail: teodorah@abv.bg

Post navigation

Previous Previous
L-cystein as nutritional supplement and technological additive – medico-biological effects and health safety
NextContinue
Erythema induratum of Bazin
Search
корица 12
All issues in 2023

Issue 12/2023

PULMONOLOGY Current guidelines for the diagnosis and treatment of COPD Yordanov, P., Dimitrova, V. The point of bronchial hyperreactivity (BHR)…

Корица - 112023
All issues in 2023

Issue 11/2023

Ear / Nose / Throat Allergic rhinitis – a risk factor for asthma Perenovska, P. Phenotypes of non allergic rhinitis…

корица 10
All issues in 2023

Issue 10/2023

Endocrinology Carcinogenic risk in obesity and diabetes mellitus Karamfilova, V., Nedeva, I. Anthropometric studies on the effect of yogurt fermented…

fb like

About us

GPNews magazine
A peer of the GP practice in our country
The only specialized edition for general practitioners
12 monthly booklets on topics vital to your practice

Menu

  • Home
  • About us
  • Contact us

Information

  • For authors
  • Publishing ethics
  • For advertising

Copyright © 2025 GPNews. All rights reserved.

Web design and SEO by Tribest

  • GDPR
Scroll to top
  • Home
  • Issues
    • 2025
    • 2024
    • 2023
    • 2022
  • Article summaries
    • AG and Neonatology
    • Allergology
    • Dental Health
    • Cardiology
    • Dermatology and Cosmetics
    • Endocrinology
    • From the Practice
    • Gastroenterology
    • History Teaches
    • In the World of Viruses
    • Nature Teaches
    • Neurology and Psychiatry
    • Nutrition, Dietetics, Metabolism
    • Oncology
    • Ophtalmology
    • Others
    • Otorhinolaryngology and Pulmonary Diseases
    • Pediatrics
    • Rheumatology and Diseases of the Joints
    • Test on a Clinical Case
    • Urology and Nephrology
  • Subscription
  • About us
  • For advertising
  • For authors
  • Publishing ethics
  • Contacts
  • GDPR
Search